Cibus Inc (CBUS)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.59+0.63%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · CBUS
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance recently climbed back into the top half of its industry — confirming the recovery.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 80.3% |
| Our one-year growth estimate | diamond | 100.0% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 19.7 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name is on a run of consecutive earnings misses and has been missing across recent quarters. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
CBUS — earnings miss
Dated 2026-08-13
of this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing, regardless of any general incorporation language in any such filing, unles…
Why it matters: Good changes in rules could help Cibus enter the market faster.
Supportive ifThe EU Parliament backs the new rules on New Genomic Techniques.
Worry ifDelays or setbacks in the EU could slow down gene editing approvals.
Why it matters: Changes in leadership can change the company's plans and how they carry them out.
Watch forPositive news on meeting short-term goals under CEO Craig Wichner.
Also watch forThere are reports of delays. There is no progress in commercialization after the leadership change.
Why it matters: If revenue growth speeds up, it can boost Cibus's performance. It shows a healthier sector.
Supportive ifSector revenue growth reported above 10% year over year.
Worry ifSector revenue growth stays below 10% year over year.
Why it matters: Earnings results will show revenue growth and cash use compared to management's goals.
Watch forRevenue over $5 million shows strong progress in key programs.
Also watch forRevenue under $3 million raises concerns about how the business is doing.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$314 on $10,000 · ±3.1% | How much price usually moves either way. |
| Bad day | $954 loss on $10,000 · 9.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,037 loss on $10,000 · 70.4% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Comparing with peers helps gauge Cibus's market position and growth potential.
Watch forCibus outperforms peers like LLY and JNJ in revenue growth.
Also watch forCibus underperforms peers in revenue growth.
Why it matters: More orders could show strong demand for Cibus's biofragrance products.
Supportive ifCibus has new orders for biofragrance products in late 2026.
Worry ifNo new scale-up orders mean weak demand for biofragrance products.
Why it matters: Staying under this limit shows Cibus's focus on costs and efficiency.
Supportive ifQuarterly net cash usage reported below $30 million for the next quarter.
Worry ifUsing over $30 million in cash each quarter shows possible money problems.
Why it matters: Success in commercializing Rice traits is key for Cibus's revenue growth. Delays could hurt investor confidence.
Watch forCibus signs a deal with at least one Rice seed partner in LATAM.
Also watch forDelays in commercialization or no new deals with Rice seed partners.
Why it matters: More changes can affect company plans. Stability helps keep investor trust.
Watch forAnnouncement of new key hires or promotions that strengthen the leadership team.
Also watch forMore leaders leaving or problems in the leadership team.